BSAC Vanguard Series: the future of ADVOCACY on AMR

Research output: Contribution to journalReview articlepeer-review

Abstract

The COVID public health emergency has brought home how vulnerable we are to forces beyond our control. We are losing our ability to treat infectious diseases for a number of reasons, including antimicrobial resistance (AMR). AMR is a ‘slow-moving’ threat, which makes it harder to recognize and address. The situation has not been helped by the difficulty we have had in seeing the actions and health of everyone on this planet as interconnected. The COVID pandemic has changed this. Despite the dire predictions of the effect of AMR in the future, we still have time to change course. Advocacy by scientists and health professionals is a powerful tool in this process, but there are pitfalls and it must be used wisely. In this article I suggest a number of ways in which this can be achieved.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalJournal of Antimicrobial Chemotherapy
Volume77
Issue number1
DOIs
StatePublished - Jan 1 2022

Bibliographical note

Publisher Copyright:
© The Author(s) 2021.

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'BSAC Vanguard Series: the future of ADVOCACY on AMR'. Together they form a unique fingerprint.

Cite this